点点互动两款产品会师全球榜单 | 排行榜 | | | | 2025年5月全球手游收入TOP10 | | | | --- | --- | --- | --- | --- | --- | --- | | | | 收入榜 | | | 收入增长榜 | | | | | Honor of Kings Tencent | = | 1 | SD Gundam G Generation BANDAI NAMCO Entertainment | | | | | Whiteout Survival Century Games | | 2 | Game For Peace Tencent | | | | 3 | Last War:Survival Game FUINFLY | | 3 | Seven Knights Re:BIRTH Netmarble Games Corp. | | | | | Royal Match Dream Games | | | Kingshot Century Games | | | | | MONOPOLY GO! | | | Brawl Stars | | | | 5 | Scopely | | | ...

企查查APP显示，近日，一汽旗新动力（长春）科技有限公司成立，注册资本5亿元，经营范围包含： 智能机器人的研发；智能机器人销售；人工智能应用软件开发；人工智能公共服务平台技术咨询服务 等。企查查股权穿透显示，该公司由中国第一汽车集团有限公司间接全资持股。 ...

公开资料显示，Vor Bio是一家纳斯达克上市的生物科技公司，股票代码VOR。截至当地时间6月25日收 盘，VOR的股价为0.5544美元/股，总市值仅为6922.8万美元（约合人民币5亿元）。 目前，市场关注的"BD"更多指创新药license out（对外授权），即管线出海。在该模式下，国内药企将 药物的后期研发和上市销售权授予海外药企，以此获得首付款、里程碑付款和销售分成。 总交易额达42.3亿美元 6月26日早间，荣昌生物（688331.SH，09995.HK）宣布，将公司具有自主知识产权的泰它西普有偿许 可给美国纳斯达克上市公司Vor Biopharma Inc.（以下简称"Vor Bio"），Vor Bio将获得泰它西普在除大 中华区以外的全球范围内开发、生产和商业化的独家权利。 同时，荣昌生物将取得Vor Bio价值1.25亿美元现金及认股权证（包括4500万美元的首付款和价值8000万 美元的认股权证，认股权证可以每股0.0001美元认购Vor Bio 3.2亿股的普通股，约占Vor Bio经扩大总发 行股本的23%）、最高可达41.05亿美元的里程碑付款，总金额42.3亿美元，此外荣昌生物还 ...

截至6月25日，软件ETF近1年净值上涨48.65%，指数股票型基金排名178/2878，居于前6.18%。从收益能力看，截至2025年6月25日，软件ETF自成立以来， 最高单月回报为39.35%，最长连涨月数为3个月，最长连涨涨幅为69.40%，上涨月份平均收益率为10.18%。 6月22日，在中国人民银行和香港金融管理局共同推动下，"跨境支付通"正式上线。跨境支付通，是指将中国内地快速支付系统与其他货币当局的快速支付 系统连接，制定配套政策安排。通过跨境支付通实现内地和香港支付系统快速互联互通，两地居民汇款将更加便捷、高效，与现有人民币跨境支付系统形成 良好互补，人民币国际化进程有望更进一步。 截至2025年6月26日 11:07，中证软件服务指数上涨0.87%，成分股恒生电子上涨6.53%，指南针上涨5.48%，卫宁健康上涨5.29%，奇安信上涨2.87%，中国软 件上涨1.44%。软件ETF(159852)上涨0.74%， 冲击4连涨。 有机构认为表示，从中长期投资逻辑来看，金融科技板块弹性十足，对流动性改善反映迅速，目前市场交投活跃度提升明显，金融科技板块有望持续受益： 互联网券商基本面预期有望持 ...

21世纪经济报道记者孙燕 上海报道 6月23日，斯坦德机器人（无锡）股份有限公司（以下简称"斯坦德机器人"）递表港交所，计划通 过"18C章程"在港交所主板挂牌上市。 斯坦德机器人成立于2016年，主要提供工业智能移动机器人解决方案、工业具身智能机器人解决方案。 工业智能移动机器人是在工业场景中具备自主导航与移动能力的智能机器人，包括AGV（自动导引 车）、AMR（自主移动机器人）等，能够自主完成路径规划、避障、物料搬运等任务。 目前，斯坦德机器人的机器人产品包括标准型机器人、功能机器人与具身机器人。 2017年，斯坦德机器人推出首款标准型机器人，一年后首次在汽车领域开展大规模交付。 标准型机器人可以无缝部署在新场景中，而无需对特定场景进行修改。随着客户工作流程的持续变化， 标准型机器人可以高效地重新部署，以满足不断变化的需求。它们还配备了一套全面的外部接口，可实 现灵活和多功能的扩展。 2020年，斯坦德机器人推出新一代功能机器人，包括背负式机器人、传输式机器人、叉取式机器人和牵 引式机器人。 相较标准型机器人，通过将其他模组整合到核心机器人技术平台中，功能机器人配备了量身定制的高级 功能以满足特定的功能需 ...

Core Viewpoint - A significant transaction worth $4.2 billion has been established between a financially troubled Chinese pharmaceutical company, Rongchang Biopharma, and a US biotech firm, Vor Biopharma, amidst a challenging capital market for innovative drugs [1][2]. Summary by Sections Transaction Details - Rongchang Biopharma has licensed its self-developed drug, Taitasip, to Vor Biopharma, granting exclusive rights for development, production, and commercialization outside Greater China [1]. - The agreement includes a cash payment of $125 million, consisting of a $45 million upfront payment and $80 million in warrants, allowing Vor Bio to issue 320 million shares at $0.0001 each, representing approximately 23% of Vor Bio's post-expansion total equity [1]. - Additionally, Rongchang Biopharma could receive up to $4.105 billion in milestone payments and sales royalties based on sales performance [1]. Financial Context of Vor Biopharma - Vor Biopharma announced a 95% workforce reduction and reported a cash reserve of $91.9 million after a $55.6 million PIPE financing, which is expected to sustain operations until Q1 2026 [2]. - Concerns have been raised regarding the viability of the partnership, given Vor Bio's precarious financial situation and the potential risks for Rongchang Biopharma [2]. Rongchang Biopharma's Financial Performance - Rongchang Biopharma reported a revenue of 1.715 billion yuan in 2024, a year-on-year increase of 58.4%, but still faced a net loss of 1.468 billion yuan [3]. - The growth in revenue was primarily driven by the strong sales of Taitasip and another key product, with Taitasip's sales exceeding 1.5 million units, up 94.87% year-on-year [3]. Clinical Pipeline and Financial Pressure - Rongchang Biopharma has 12 drugs in phase III clinical trials, with nearly half undergoing international trials, indicating high investment requirements [4]. - The company reported a cash balance of 762 million yuan and total borrowings exceeding 2.5 billion yuan, leading to a debt ratio of 63.88% [4]. Market Dynamics and Strategic Shifts - The traditional "out-licensing" model is evolving, with a new "NewCo" model emerging, where companies collaborate to create new entities, sharing risks and rewards [6][9]. - The partnership between Rongchang Biopharma and Vor Bio is seen as a shift towards this NewCo model, although the sustainability of this structure remains uncertain given Vor Bio's financial commitments [6][10]. Industry Implications - The transaction highlights the necessity for Chinese pharmaceutical companies to explore international partnerships as a means of securing funding and market access [8]. - The increasing trend of out-licensing and the creation of NewCo structures reflect a strategic response to the challenges faced in the global pharmaceutical market [8][9].

Group 1 - The core point of the news is the recent personnel changes at Hualin Securities, including the election results of the fourth board of directors and the appointment of senior management [2][3] - Lin Li has been re-elected as the chairman of the board, receiving unanimous votes during the first meeting of the fourth board [3] - The new board consists of five members, including non-independent directors Lin Li, Zhang Zesheng, and employee director Wan Li, along with independent directors Tian Lihui and Li Weidong [3][6] Group 2 - A total of 11 senior management personnel appointments were announced, with 9 being reappointments and 2 newly appointed [7] - Key reappointments include Qin Xiang as CEO, Liang Rindong as compliance director and chief risk officer, and Xie Yingming as board secretary [7][8] - New appointments include Wu Qiuna as financial director and Wu Weizhong as chief information officer, both promoted internally [8][9] Group 3 - Hualin Securities reported strong financial performance in the latest 2024 financial report, achieving revenue of 1.435 billion yuan, a year-on-year increase of over 41%, and a net profit of 353 million yuan, a year-on-year increase of approximately 1015% [9]

7月作为下半年车市开局之月，众多车企将推出重磅新车抢占市场。以下是本月值得关注的上市新车盘点，涵盖燃油、混动及纯电车型，为消费者提供 多样化选择。 比亚迪海狮06：主打科技感与实用性 比亚迪海狮06是比亚迪海洋网即将推出的中型SUV，包括插电混动（DM-i）和纯电（EV）版本，采用第五代DM技术和e平台3.0 Evo打造，价格为16万 元-20万元。 造型依旧采用海洋美学的设计风格，车头为封闭式格栅，两侧配备双层前大灯，该车也是海洋网首款采用分体式大灯的车型。车身侧面，车顶线条向后 下沉，搭配悬浮式车顶设计，提升时尚感。环形贯穿式尾灯采用"水滴"造型，内部经过熏黑处理，点亮后具有不错的辨识度。 内部采用简约科技风格，嵌入式全液晶仪表盘与大尺寸悬浮式中控屏形成双屏布局。中央扶手区域，车辆将配备无线充电以及启动按钮等常用的物理按 键。 动力方面，海狮06 DM-i/EV分别采用第五代DM技术和e平台3.0 Evo打造。其中，插混版搭载的1.5L发动机最大功率74kW，电机最大功率160kW，配备 18.3kWh和26.6kWh电池组，WLTC工况下纯电续航里程分别为93km和130km；纯电车型提供两驱和四驱车型 ...

Group 1 - China Yangtze Power Co., Ltd. has obtained a patent for a tool cabinet designed for the convenient placement of long ladders, with the patent number CN223013167U and application date of August 2024 [1] - The patent describes a tool cabinet that includes a storage cabinet located on top of a ladder placement rack, which consists of multiple vertical rods and horizontal rods, providing a designated space for placing long ladders [1] - The design addresses safety hazards associated with leaning ladders against walls and the difficulty of neatly storing ladders on the ground, thereby optimizing space utilization [1] Group 2 - China Yangtze Power Co., Ltd. was established in 2002 and is based in Beijing, primarily engaged in the production and supply of electricity and heat [2] - The company has a registered capital of approximately 2.45 billion RMB and has made investments in 46 enterprises, participated in 5,000 bidding projects, and holds 250 trademark registrations and 5,000 patent registrations [2] - Additionally, the company possesses 431 administrative licenses, indicating a robust operational framework [2]

Core Insights - The company is experiencing a new wave of growth opportunities in the competitive home appliance market, driven by precise user demand insights and innovative vitality [1] - The capital market has highly recognized the company's strategic transformation, with multiple institutions providing positive ratings and target prices [1][2] Product Innovation - The company launched the ultra-thin 1mm Light Pro Warm Palace Belt in June, addressing user pain points with features like 5-level precise temperature control and antibacterial materials [1] - The split electric stew pot meets the upgraded needs of family kitchens, and promotional strategies have effectively stimulated sales [1] - The company conducts over 20,000 user surveys annually through its "User Direct Plan," leading to rapid growth in its maternal and infant product category, with projected revenue of 250 million yuan in 2024 [1] Strategic Transformation - The company is focusing on high-end flagship products by shrinking low-profit categories and ensuring quality and capacity through smart manufacturing bases and a 2000㎡ testing center [2] - AI technology is applied in the digital field to optimize the supply chain and enhance market response speed through an integrated development system [2] - The company employs a dual-track strategy of "own brand + OEM" for global expansion, increasing R&D investment in Southeast Asia, Japan, South Korea, and Europe while leveraging established channels through OEM/ODM business [2] Financial Performance - The company has seen a decrease in sales expense ratio by 2.55 percentage points year-on-year and an increase in net profit margin by 3.18 percentage points quarter-on-quarter in Q1 2025, indicating improved operational quality [1] - The company is building resilience against challenges like raw material cost pressures through product innovation, efficiency improvements, and strategic focus [2] Market Outlook - The differentiated layout in the health small appliance sector, continuous optimization of the profit model, and steady progress in globalization collectively depict a new landscape for high-quality development [2] - The combination of "User Direct" innovation and refined operational capabilities positions the company for promising growth potential in the market [2]